AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: SGMO
Report Date: 2026-04-24
Full Report: https://amaly.io/stock/SGMO

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Sangamo Therapeutics (SGMO), a clinical-stage biotechnology company focused on genomic medicines, demonstrates compliant debt and liquidity ratios but fails due to an interest income ratio of 10.14% exceeding the 5% threshold across standards. Business activities in gene therapy are permissible under Shariah principles. The company is not included in any major Shariah indices, leading to an overall non-compliant status. Purification of 10.14% of dividends is required. Investors should monitor financial improvements and consult scholars for personalized rulings.

Primary Compliance Concerns:
- Interest income ratio of 10.14% exceeds 5% threshold

Purification Requirement: 10.14%
Index Inclusion: Not included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, or Dow Jones Islamic Market (DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 15.9%
Liquidity Ratio: 16.1%
Interest Income Ratio: 10.1%
Purification Required: 10.14%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-01-30T12:00:00Z

---
Full interactive report: https://amaly.io/stock/SGMO
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.